Abbott reports 45 percent lower death odds for Abbott Laboratories stock

Published on 10/16/2026 at 09:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott cited 54 percent lower cancer incidence on October 12, 2026. Abbott Laboratories stock costs EUR 93.23 on October 16, 2026 versus EUR 93.44.

Cologuard evidence and earnings calendar

Abbott reported 45 percent lower odds of death after screening on October 12, 2026.
Second-quarter revenue reached USD 12.59 billion, up 13 percent year over year.
Abbott Laboratories stock trades at EUR 93.23 at 9:33 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.22 percent below the Xetra close of October 15, 2026.
Third-quarter results are scheduled for October 21, 2026.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) reported that completing its Cologuard screening was associated with 45 percent lower odds of death after a colorectal cancer diagnosis. The company published the findings on October 12, 2026, as part of research presented at the American College of Gastroenterology meeting, according to Abbott MediaRoom.

Cologuard evidence adds a quantified catalyst

The same nationwide research linked completed multitarget stool DNA screening with 54 percent lower adjusted colorectal cancer incidence among more than 2.5 million average-risk adults. A separate case-control study covered 5,745 people diagnosed with colorectal cancer, giving Abbott's screening portfolio a large evidence base for the latest announcement.

The findings concern clinical associations rather than a new sales forecast. For investors, the commercial question is how evidence and adherence translate into wider use of Cologuard and Cologuard Plus, which Abbott markets alongside diagnostics, medical devices, nutrition products and branded generic medicines.

What does the earnings setup show?

Abbott's second-quarter revenue reached USD 12.59 billion, up 13 percent from the year-earlier period, while diluted earnings per share were USD 0.53. The finance figures cover the quarter ended June 30, 2026. Earlier reporting cited adjusted earnings per share of USD 1.31 and revenue of USD 12.59 billion for the previous reported quarter, versus consensus of USD 1.28 and USD 12.52 billion, respectively, according to MarketBeat.

Three dates chart the recent path

On September 17, 2026, Abbott declared a quarterly dividend of USD 0.63 per share. On October 7, 2026, it introduced Ensure Max Protein 3-in-1 with 30 grams of protein. On October 12, 2026, it published the Cologuard evidence linking screening with 54 percent lower cancer incidence and 45 percent lower odds of death, with the chronology reported by El Fondo.

Upcoming results set the next test

Abbott is scheduled to report third-quarter results before the market opens on October 21, 2026. MarketBeat cites consensus estimates of USD 1.42 adjusted earnings per share and USD 13.00 billion in revenue, against company guidance of USD 1.38 to USD 1.46 adjusted earnings per share. The company is also scheduled to pay the USD 0.63 dividend on November 16, 2026, according to MarketBeat.

Stock price stays below the Xetra close

Abbott Laboratories stock was trading at EUR 93.23 at Lang & Schwarz on October 16, 2026 at 9:33 a.m. CEST, 0.22 percent below the Xetra close of October 15, 2026 at EUR 93.44. The primary listing is on the NYSE, where the stock was last quoted at USD 104.69 on October 15, 2026 at 3:59 p.m. ET. The euro quote remains the relevant reference for investors in Germany.

The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.